Compugen

CGENNasdaq Israel Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$230.314 M

$2.44 -2.21%

Close of 21 Sept 2026

Revenue

$72.8M

#2608 by revenue

Earnings

$35.3M

#1692 by earnings

Shares outstanding

94,553,191

Latest filing cover page

P/E ratio

6.5

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#89Sutro BiopharmaSTRO$271.1M
#90Lineage Cell TherapeuticsLCTX$255.4M
#91CompugenCGEN$230.3M
#92Cardiol TherapeuticsCRDL$224.4M
#93Anavex Life SciencesAVXL$222.5M

What if Compugen were worth as much as…

Open the what-if tool →

Gold $30.3T

$320,073.70

Per share 131,447× higher

Bitcoin $1.72T

$18,182.70

Per share 7,467× higher

Nvidia $5.48T

$57,936.03

Per share 23,793× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Compugen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.